Skip to main navigation

Skip to main content

About
Approach
Pipeline
Patients
Investors
Careers

News Releases

Investors |
news and events |
News Releases

Investors

Investor Relations

Overview
News and Events
- News Releases
- Events
Corporate Presentation
- Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Corporate Governance
Financial Information
- SEC Filings
- Annual Reports & Proxy
Investor Resources

Year

Aug 11, 2022

DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights

Jul 21, 2022

DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis

Jun 01, 2022

DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference

May 12, 2022

DICE Therapeutics Reports First Quarter 2022 Financial Results and Recent Highlights

May 03, 2022

DICE Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

Mar 28, 2022

DICE Therapeutics Expands Management Team and Board of Directors

Mar 21, 2022

DICE Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

Feb 10, 2022

DICE Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Careers
News
Contact Us
Privacy Policy
Terms of Use

400 East Jamie Court
Suite 300
South San Francisco
CA 94080

DICE Therapeutics ©2022